Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders-Reference-Cited by-同舟云学术

Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders

Published:2021-10-06 Issue:19 Volume:64 Page:14773-14792
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Turdi Huji,Chao Hannguang,Hangeland Jon J.^ORCID,Ahmad Saleem,Meng Wei,Brigance Robert,Zhao Guohua,Wang Wei,Moore Fang,Ye Xiang-Yang,Mathur Arvind,Hou Xiaoping^ORCID,Kempson James^ORCID,Wu Dauh-Rurng,Li Yi-Xin,Azzara Anthony V.,Ma Zhengping,Chu Ching-Hsuen,Chen Luping,Cullen Mary Jane,Rooney Suzanne,Harvey Susan,Kopcho Lisa,Panemangelor Reshma,Abell Lynn,O’Malley Kevin,Keim William J.,Dierks Elizabeth,Chang Shu,Foster Kimberly,Apedo Atsu,Harden David,Dabros Marta,Gao Qi,Pelleymounter Mary Ann,Whaley Jean M.,Robl Jeffrey A.,Cheng Dong,Lawrence R. Michael,Devasthale Pratik^ORCID

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01356

Reference43 articles.

1. Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

2. MOGAT2: A New Therapeutic Target for Metabolic Syndrome

3. MGAT2, a Monoacylglycerol Acyltransferase Expressed in the Small Intestine

4. Cloning and Functional Characterization of a Mouse Intestinal Acyl-CoA:Monoacylglycerol Acyltransferase, MGAT2

5. Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Syntheses of Substituted α,β-Unsaturated δ-Lactams from N-Boc-2,4-dioxopiperidine;The Journal of Organic Chemistry;2023-11-22

2. Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders;Journal of Medicinal Chemistry;2023-09-19

3. Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders;Bioorganic & Medicinal Chemistry Letters;2023-07

4. An Analysis of Successful Hit-to-Clinical Candidate Pairs;Journal of Medicinal Chemistry;2023-05-24

5. Synthesis of 3,4-Dihydropyridin-2-ones via Domino Reaction under Phase Transfer Catalysis Conditions;Catalysts;2023-01-11